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Abstract
Pneumocystis jirovecii pneumonia (PCP) is an important opportunistic infection in patients infected with HIV, but its burden
is incompletely characterized in those areas of sub-Saharan Africa where HIV is prevalent. We explored the prevalence of
both PCP in HIV-infected adults admitted with pneumonia to a tertiary-care hospital in Uganda and of putative P. jirovecii
drug resistance by mutations in fungal dihydropteroate synthase (dhps) and dihydrofolate reductase (dhfr). In 129
consecutive patients with sputum smears negative for mycobacteria, 5 (3.9%) were diagnosed with PCP by microscopic
examination of Giemsa-stained bronchoalveolar lavage fluid. Concordance was 100% between Giemsa stain and PCR (dhps
and dhfr). PCP was more prevalent in patients newly-diagnosed with HIV (11.4%) than in patients with known HIV (1.1%;
p = 0.007). Mortality at 2 months after discharge was 29% overall: 28% among PCP-negative patients, and 60% (3 of 5)
among PCP-positive patients. In these 5 fungal isolates and an additional 8 from consecutive cases of PCP, all strains
harbored mutant dhps haplotypes; all 13 isolates harbored the P57S mutation in dhps, and 3 (23%) also harbored the T55A
mutation. No non-synonymous dhfr mutations were detected. PCP is an important cause of pneumonia in patients newly-
diagnosed with HIV in Uganda, is associated with high mortality, and putative molecular evidence of drug resistance is
prevalent. Given the reliability of field diagnosis in our cohort, future studies in sub-Saharan Africa can investigate the
clinical impact of these genotypes.
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Introduction
Pneumocystis jirovecii pneumonia (PCP) is a major opportunistic
infection in people with HIV and AIDS. In the United States and
Europe, its incidence has decreased dramatically among HIV-
infected patients owing to the twin interventions of antimicrobial
prophylaxis of high-risk patients and combination antiretroviral
(ARV) therapy. However, in sub-Saharan Africa, access to these
interventions remains limited for the 23 million people living with
HIV infection; recent estimates indicate that the prevalence of
PCP amongst HIV-infected patients with pneumonia may be as
high as 27% in some African countries [1].
PCP prophylaxis decreases the risks of PCP, PCP-related death,
and all-cause death amongst patients with AIDS. [2] However,
putative P. jirovecii drug resistance threatens the durability of PCP
prophylaxis with antifolate antibiotics, which are the mainstay of
PCP prevention amongst high-risk patients. Antifolate drugs target
two enzymes that are necessary for the fungus to synthesize folate
– dihydropteroate synthase (DHPS) and dihydrofolate reductase
(DHFR) – and mutations in the genes encoding these proteins (dhps
and dhfr, respectively) are associated with reduced in vitro drug
efficacy. [3,4] Because drug efficacy cannot be directly assessed in
the absence of a reliable P. jirovecii cultivation system, and because
the presence of several mutations is consistently associated with
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exposure to antifolates, [5] these mutations may represent a
genetic signature of clinical drug resistance. In the United States
and Europe, the prevalence of two of the most common dhps
mutations (those at codons 55 and 57) in patients with PCP has
been reported between 23–81% (in the USA) and 7–57% (in
Europe). [6] Estimates of the independent effect of P. jirovecii
mutants upon clinical outcomes have been conflicting: some
studies report their association with increased mortality or
antifolate-based treatment failure, [7–10] while others have not
[11–13].
Despite the potential high burden of PCP in sub-Saharan
Africa, few studies have explored P. jirovecii dhps and dhfr genotypes
in HIV-infected patients in this region, and no studies have done
so outside of Southern Africa. [14,15] We investigated P. jirovecii
among a cohort of HIV-infected patients admitted to Mulago
Hospital, a national referral center in Kampala, Uganda. We
assessed the prevalence both of PCP amongst patients with
pneumonia and of P. jirovecii mutations associated with antifolate
drug resistance. We hypothesized that PCP would be common and




The study was approved by institutional review boards at
Mulago Hospital and Makerere University, the University of
California, San Francisco, the University of North Carolina at
Chapel Hill, and by the Uganda National Council for Science and
Technology. All patients provided written informed consent.
Patient Enrollment and Sample Collection
For this study, P. jirovecii molecular testing was employed in two
phases in an effort to first assess the prevalence of PCP amongst
HIV-infected patients with pneumonia and subsequently to assess
the prevalence of mutant P. jirovecii genotypes among patients with
microscopically-confirmed PCP while also optimizing resources.
In phase 1, we tested consecutively-enrolled patients meeting the
criteria below between September 2007 and July 2008, to
determine the prevalence of PCP at Mulago Hospital and to
allow for comparison of Pneumocystis detection by microscopy and
PCR. After we found a low prevalence of PCP in phase 1, in phase
2, we obtained molecular sequence data from only those patients
with microscopically-diagnosed PCP between September 2008
and October 2009.
Details of the clinical study have been described previously. [16]
Briefly, consecutive patients that were admitted to Mulago
Hospital were screened; patients were offered enrollment if they
were HIV-positive, had cough $2 weeks but ,6 months, and
received a clinical diagnosis of pneumonia. All patients had a chest
x-ray and provided two sputum samples for examination for acid-
fast bacilli (AFB) by direct Ziehl-Neelsen microscopy. Clinical
outcome was assessed either in person or by telephone interview at
2 months after discharge.
Patients with sputa negative for AFB were referred for
bronchoscopy. Two experienced pulmonologists performed bron-
choscopies by completely visualizing central airways and lavaging
the radiographically-most-affected lobe of the lung with up to
125 mL of sterile normal saline. Trained laboratory technicians in
the Microbiology Department at Mulago Hospital performed all
initial examinations of BAL fluid, including modified Giemsa stain
for P. jirovecii; Giemsa-stained BAL fluid was subsequently assessed
by a second reader at San Francisco General Hospital who was
masked to other clinical and laboratory data. Aliquots of 1–2 mL
of unprocessed BAL fluid were frozen at 220uC for subsequent
molecular analyses.
Molecular Methods
PCR testing was performed at the University of North Carolina
by personnel masked to clinical and microscopic diagnoses. BAL
specimens were thawed and briefly vortexed. Genomic DNA
(gDNA) was extracted from 200 mL of each BAL specimen using
the EZ1 Virus Mini Kit v2.0 (Qiagen, Valencia, CA). Individual
samples were amplified in nested PCR assays targeting the dhps
and dhfr genes of P. jirovecii. [17,18] Products were electrophoresed
on 1% agarose gels, with amplification confirmed by the presence
of a single band at 330 base pairs (for dhps) or at 850 base pairs (for
dhfr). Separate work areas for gDNA extraction, reaction set-up,
and electrophoresis were maintained to minimize contamination
of the PCR testing, and all reaction plates included negative and
positive controls with either molecular-grade water or gDNA from
a patient with known PCP, respectively.
Samples demonstrating amplification were purified with the
QIAquick Gel Extraction Kit (Qiagen). Purified products were
bidirectionally sequenced using ABI BigDye Terminator chemistry
at the UNC Core Sequencing Facility. Sequences were aligned
with Sequencher v4.8 (Gene Codes, Ann Arbor, MI). Wildtype
P. jirovecii sequences obtained from GenBank were used as
referents for alignments: U66282 for dhps and AF090368 for dhfr.
Base calls at loci corresponding to codons 55 and 57 of dhps were
confirmed by manual inspection of the chromatograms of contigs
that were built from both forward and reverse sequencing reads.
Aligned sequences were manually inspected both for mixed alleles
(defined as peaks $10% of primary peak, above baseline) and for
mutations at other loci (including those in the sequenced fragment
of dhfr); novel mutations were defined as single nucleotide
polymorphisms evident in both sequences obtained from the same
amplicon at a locus not described above.
Definitions and Statistical Analyses
Haplotypes for dhps were assigned based upon codons 55 and
57: ‘‘Wildtype’’ refers to isolates with wildtype alleles at both loci,
‘‘single-mutant’’ to isolates with a wildtype allele at only one locus,
and ‘‘double-mutant’’ to isolates with mutant alleles at both loci.
For haplotype assignment, mixed alleles were classified as mutant.
We compared demographic and clinical data between patients
with and without PCP with the student’s t-test or Kruskal-Wallis
test for continuous variables, or with the chi-squared test for
categorical variables. We compared agreement between PCP
diagnosis by modified Giemsa stain and PCR using Cohen’s
kappa. All statistical analyses were conducted with Stata/IC
(version 10, Stata Corp., College Station, TX).
Results
Prevalence of PCP
In phase 1 overall, 407 consecutive patients were enrolled
and 218 (54%) were eligible for bronchoscopy; 132 patients
(32%) ultimately underwent bronchoscopy and BAL. Therefore,
129 patients were investigated in phase 1 (three specimens were
missing), and clinical characteristics were similar between those
who did and did not undergo bronchoscopy. [19] Mean (SD)
age of these 129 patients was 34 years (9.1), and 73 (57%) were
women. Ninety-four patients (73%) had been previously
diagnosed with HIV. Among these 94 patients, 22 (23.4%)
were taking antiretrovirals on admission, and 77 (81%) reported
taking PCP prophylaxis (76 with trimethoprim-sulfamethoxazole,
1 with dapsone). The median (interquartile range) CD4 cell
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count among 128 patients with available values was 74 cells/
mm3 (17–192), and 98 patients (77%) had a CD4 cell count
below 200 cells/mm3.
As previously described, the most frequent pulmonary diagnoses
in these patients who underwent bronchoscopy were pulmonary
tuberculosis (TB), pulmonary cryptococcosis, pulmonary Kaposi
sarcoma, and PCP. [20] By microscopic evaluation of modified
Giemsa-stained BAL specimens, five patients (3.9%) were diag-
nosed with PCP. Two patients were diagnosed with PCP alone,
and one patient each was also co-infected with pulmonary
Cryptococcus neoformans, culture-positive pulmonary tuberculosis, or
culture-negative pulmonary tuberculosis. Four of the five were
newly diagnosed with HIV; all five had CD4 cell counts below 50
cells/mm3, and none were taking antiretrovirals or PCP prophy-
laxis. Overall mortality at 2 months after discharge was 29% (38 of
129): 28% of non-PCP patients had died (35 of 124), compared
with 60% of PCP patients (3 of 5; Risk Ratio 2.13; 95% C.I. 0.98–
4.59).
Five patients (3.9%) were positive in the both of the PCR assays
targeting dhps and dhfr. Agreement between detection by micros-
copy and PCR was 100% (p,0.001). Additionally, agreement
between the reader at Mulago Hospital and the second, masked
reader at San Francisco General Hospital was also 100%.
Prevalence of dhps and dhfr Genotypes
In total, 13 dhps and dhfr sequences were available (5 from phase
1 and an additional 8 from phase 2) (Table 1). All 13 isolates
harbored the P57S mutation in dhps; in one specimen, the
mutation was present in addition to the wildtype allele. Only 3
(23%) harbored the T55A mutation; in one specimen, the
mutation was present with the wildtype allele.
The single-mutant dhps haplotype was present in 10/13 (77%)
specimens, and the double-mutant dhps haplotype was present in
the remaining three. Thus, there were no wildtype dhps haplotypes
present.
In 12 of 13 specimens dhfr was wildtype across the sequenced
loci. One specimen demonstrated a synonymous thymidine to
cytosine substitution at base pair 1437 of the reference sequence.
Thus, none of the isolates harbored mutant DHFR enzymes.
Clinical and Molecular Correlates
There were no significant differences in the mean age or gender
distribution of patients with and without PCP (Table 2). All
patients with PCP had a CD4 count ,200 cells/mm3; median
CD4 cell count was lower among patients diagnosed with PCP (12
cells/mm3) than without (88; p = 0.033 by Kruskal-Wallis). No
PCP patients were taking antiretrovirals on admission.
PCP was significantly more prevalent among the 35 patients
newly diagnosed with HIV (11.4%) than the 94 patients with
previously-diagnosed HIV (1.1%; p = 0.007). Among the 94
patients with known HIV, PCP was diagnosed in 1 of 17 (5.9%)
not taking PCP prophylaxis and 0 of 77 who reported receiving
PCP prophylaxis (p = 0.032).
Among the 13 total patients with PCP, the dhps double mutant
was present in 1 of 2 patients taking PCP prophylaxis (both with
trimethoprim-sulfamethoxazole) and 2 of 11 (18.2%) not taking
prophylaxis (p = 0.326). Only 1 dhfr mutant was identified, this in a
patient not taking PCP prophylaxis. The absence of wildtype dhps
genotypes precluded a meaningful assessment of the effect of dhps
genotype upon clinical PCP outcome.
Discussion
In this cross-sectional study of HIV-infected Ugandans admitted
to a tertiary care hospital with pneumonia who underwent
bronchoscopy, the prevalence of Pneumocystis pneumonia was low,
but all P. jirovecii isolates harbored mutations in the dhps gene.
These mutations are putatively associated with antifolate resis-
tance based upon epidemiologic evidence and experience with
other pathogens. Additionally, the field diagnosis of PCP using
Giemsa staining demonstrated excellent concordance with molec-
ular diagnosis. Because PCP remains an important opportunistic
infection in HIV-infected patients that are not receiving PCP
prophylaxis, these findings have important implications for the
care of patients with AIDS in sub-Saharan Africa.
Our data indicate that P. jirovecii is now an uncommon etiology
of pneumonia in hospitalized, HIV-infected patients in Kampala,
Uganda. Reported prevalences of PCP in sub-Saharan African
settings vary widely, including 4% in the Central African
Republic, [21] 5% in Bujumbura, [22] 5% in Kigali, [23] 8% in
Dakar, [21] 8% in Moshi, [24] 27% in Blantyre, [1] 30% in Addis
Ababa, [25] and 33% in Harare. [26] Indeed, the prevalence of
PCP (diagnosed using an immunofluorescent antibody test) was
39% among patients admitted to Mulago Hospital and enrolled
with similar criteria to ours between 1999 and 2000. [27]
Importantly, only 25% of patients in the earlier cohort reported
by Worodria et al. reported receiving cotrimoxazole prior to
admission, [27] while in our cohort, 60% of all patients and 81%
of those who were previously-diagnosed with HIV received PCP
prophylaxis. Our study was not designed to assess the efficacy of
PCP prophylaxis, but among patients with known HIV, we do
note a significant negative association between PCP diagnosis and
the receipt of PCP prophylaxis. Therefore, the successful provision
of PCP prophylaxis to HIV-infected patients in Kampala that
comprised our cohort may have reduced the overall prevalence of
PCP.
Despite the low overall PCP prevalence, among patients newly-
diagnosed with HIV, the prevalence of PCP was 11.4%, indicating
that PCP remains a significant clinical concern in those newly-
diagnosed with HIV or not on PCP prophylaxis. Our study
highlights the applicability of microscopic examination of modified
Giemsa-stained pulmonary specimens for field diagnosis of PCP:
Agreement was 100% between this technique and PCR at the dhps
and dhfr loci. Several studies in high income settings have
Table 1. Prevalence of P. jirovecii genotypes.






Single mutant 10 (76.9)




dhps: dihydropteroate synthase; dhfr: dihydrofolate reductase. Patients with
mixed alleles were classified as mutant.
*The single dhfr polymorphism encoded a synonymous mutation at base pair
1437 of the reference sequence AF090368.
doi:10.1371/journal.pone.0049991.t001
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described the performance characteristics of the modified Giemsa
method in comparison with staining with Grocott’s methenamine
silver and toluidine blue-O or direct and indirect immunofluores-
cence staining, [28,29] but its performance has not been formally
reported from low- and middle-income settings, where the burdens
of AIDS and PCP are greatest. Though immunofluorescent
staining is most commonly employed for diagnosis in high income
settings, its expense precludes its wide use in many low- and
middle-income settings. Our data suggest that the less-expensive
modified Giemsa stain is a viable option for reliable PCP diagnosis
in settings with high prevalences of HIV in settings such as sub-
Saharan Africa.
All patients in our study harbored mutant P. jirovecii dhps isolates.
Though this may derive from a small sample size, this is notable
both because it exceeds prevalences reported in other regions and
because most patients individually denied prior exposure to PCP
prophylaxis with antifolate drugs, which is commonly associated
with the presence of P. jirovecii mutations. [5] Prevalences of
mutant P. jirovecii dhps genotypes vary geographically, [6,30] and
are generally highest in high income settings. [31] Fewer reports
have reported prevalences from sub-Saharan Africa, though 56%
of isolates from South Africa in 2006 harbored mutant dhps
haplotypes. [14] The high prevalence in our study despite the lack
of individual antifolate PCP prophylaxis may derive from two non-
exclusive processes: interhuman transmission of mutant strains or
population-level selective pressure exerted by antifolate use for
other indications. Interhuman transmission of mutant strains has
been inferred from ecological studies of mutant genotypes in which
geographic residence was associated with genotype. [30] Though
the factors that mediate the transmission of P. jirovecii remain
incompletely understood, two additional findings in Uganda argue
against this explanation. Specimens with mutant dhps haplotypes
were not clonal, as we detected 3 different haplotypes of the
P. jirovecii mitochondrial large subunit of ribosomal DNA in
specimens with identical mutant dhps haplotypes. [16] Addition-
ally, P. jirovecii colonization – one putative reservoir for interhuman
transmission – was rare in our cohort, with only 6% of patients
with non-Pneumocystis pneumonia harboring P. jirovecii DNA as
measured by a different genomic marker that amplifies a multi-
copy gene as opposed to the single-copy dhps and dhfr genes. [16]
Taken together, the non-clonality of mutant strains and the low
prevalence of P. jirovecii colonization suggest that interhuman
transmission was not primarily responsible for the high prevalence
of mutant Pneumocystis.
Notably, all patients in our study harbored Pneumocystis strains
with the dhps P57S mutation, and this near-fixation of the P57S
mutation suggests significant population-level selective pressure.
Notably, the pattern of mutant haplotypes – with a preponderance
of single-mutant P57S haplotypes – is similar to that observed in a
study from France, wherein a high prevalence of these haplotypes
was associated with the use of sulfadoxine-pyrimethamine (SP, or
Fansidar) as prophylaxis as compared with the use of trimetho-
prim-sulfamethoxazole (co-trimoxazole). [32] SP use is prevalent is
Uganda: until recently, SP was recommended first-line therapy for
malaria, and at the time of this study was still commonly used for
treatment of suspected malaria. [33] Taken together, the previous
literature linking SP and the P57S mutation, the high prevalence
of the P57S mutation in our study, and the widespread use of SP in
Uganda during this period, suggest that sulfadoxine may
differentially select for the P57S mutation in the dhps gene of P.
jirovecii.
We observed no non-synonymous mutations in the sequenced
segment of dhfr. Mutations in P. jirovecii dhfr vary greatly in
prevalence and allele between published studies, [12,18,34] and in
some settings non-synonymous mutations have been associated
with the receipt of pyrimethamine-containing PCP prophylaxis.
[35] Though we failed to detect any such mutations, the small
sample size of dhfr haplotypes in our cohort precludes inferences of
selection pressure on P. jirovecii dhfr haplotypes in Uganda.
Our study has several limitations. The high prevalence of PCP
prophylaxis use likely reduced the prevalence of PCP in our cohort
and may fetter comparison with other settings where PCP
prevalence is higher. Additionally, though concordance between
microscopic and molecular diagnosis was excellent, the use of BAL
specimens in our study may limit the generalizability of this
observation. Furthermore, a number of eligible patients did not
undergo bronchoscopy owing to patient refusal, death, or the
establishment of an alternate firm diagnosis, [20] and so the true
prevalence of PCP cannot be determined conclusively. Clinical
data that are commonly employed to gauge the likelihood of PCP
– including serum lactate dehydrogenase, arterial blood gas, chest
radiograph – were not uniformly obtained, precluding assessment
of their relationship to microscopically-confirmed PCP in this
setting. Finally, the limited number of fungal genotypes prevented
Table 2. Comparison of 129 consecutive HIV-infected patients with and without Pneumocystis pneumonia (PCP).
PCP-positive (n = 5) PCP-negative (n = 124) p-value*
Age, yr, mean (SD) 35.2 (8.9) 34.0 (9.1) 0.78
Women, no. (%) 2 (40) 71 (57.3) 0.45
CD4 cell count, cells/ml, median (interquartile range) 12 (10–39) 88 (22–196) 0.033
CD4 cells,200 cells/ml, % 5 (100) 93 (75.6) 0.21
New HIV diagnosis, no. (%) 4 (80) 31 (25) 0.007
Taking PCP prophylaxis**, no. (%) 0 (0) 77 (82.8) 0.03
Receiving antiretrovirals**, no. (%) 0 (0) 22 (23.7) 0.58
Positive PCR assay, no. (%)
dhps 5 (100) 0 NA
dhfr 5 (100) 0 NA
HIV: human immunodeficiency virus; PCR: polymerase chain reaction; dhps: dihydropteroate synthase; dhfr: dihydrofolate reductase; NA: not applicable.
*Determined by the student’s t-test or Kruskal-Wallis test for continuous variables, or the chi-squared test for categorical variables.
**Among 94 patients with previously-diagnosed HIV.
doi:10.1371/journal.pone.0049991.t002
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a fuller characterization of the relationship between clinical and
molecular data and continued study is warranted.
Our study of pneumonia amongst HIV-infected Ugandans
highlights the need to consider PCP as an etiology of pneumonia
in sputum AFB smear-negative patients with newly-diagnosed
HIV and those not on PCP prophylaxis in Uganda, and describes
a clinically- and cost-effective method for field diagnosis.
Additionally, we describe the near-fixation of a specific P. jirovecii
dhps mutation, which may be associated with patterns of sulfa
antibiotic use. Given the high prevalence of this haplotype which is
associated with drug resistance and the large population at risk of
PCP in sub-Saharan Africa, future studies are required to more
definitively characterize the clinical impact of these mutations.
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